Natural killer T cells in allergic asthma: implications for the development of novel immunotherapeutical strategies

Allergic asthma has emerged as a prevalent allergic disease worldwide, affecting most prominently both young individuals and lower-income populations in developing and developed countries. To devise effective and curative immunotherapy, it is crucial to comprehend the intricate nature of this condit...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Cristián Gutiérrez-Vera [verfasserIn] Richard García-Betancourt [verfasserIn] Pablo A. Palacios [verfasserIn] Marioly Müller [verfasserIn] David A. Montero [verfasserIn] Carlos Verdugo [verfasserIn] Francisca Ortiz [verfasserIn] Felipe Simon [verfasserIn] Alexis M. Kalergis [verfasserIn] Pablo A. González [verfasserIn] Noemi A. Saavedra-Avila [verfasserIn] Steven A. Porcelli [verfasserIn] Leandro J. Carreño [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2024

Schlagwörter:	natural killer T cells allergic diseases asthma immunomodulation immunotherapy

Übergeordnetes Werk:	In: Frontiers in Immunology - Frontiers Media S.A., 2011, 15(2024)
Übergeordnetes Werk:	volume:15 ; year:2024

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.3389/fimmu.2024.1364774

Katalog-ID:	DOAJ09248204X

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ09248204X
003	DE-627
005	20240414123926.0
007	cr uuu---uuuuu
008	240412s2024 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.3389/fimmu.2024.1364774 \|2 doi
035			\|a (DE-627)DOAJ09248204X
035			\|a (DE-599)DOAJ55b69705c197419b983dae990d8a8d06
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RC581-607
100	0		\|a Cristián Gutiérrez-Vera \|e verfasserin \|4 aut
245	1	0	\|a Natural killer T cells in allergic asthma: implications for the development of novel immunotherapeutical strategies
264		1	\|c 2024
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Allergic asthma has emerged as a prevalent allergic disease worldwide, affecting most prominently both young individuals and lower-income populations in developing and developed countries. To devise effective and curative immunotherapy, it is crucial to comprehend the intricate nature of this condition, characterized by an immune response imbalance that favors a proinflammatory profile orchestrated by diverse subsets of immune cells. Although the involvement of Natural Killer T (NKT) cells in asthma pathology is frequently implied, their specific contributions to disease onset and progression remain incompletely understood. Given their remarkable ability to modulate the immune response through the rapid secretion of various cytokines, NKT cells represent a promising target for the development of effective immunotherapy against allergic asthma. This review provides a comprehensive summary of the current understanding of NKT cells in the context of allergic asthma, along with novel therapeutic approaches that leverage the functional response of these cells.
650		4	\|a natural killer T cells
650		4	\|a allergic diseases
650		4	\|a asthma
650		4	\|a immunomodulation
650		4	\|a immunotherapy
653		0	\|a Immunologic diseases. Allergy
700	0		\|a Cristián Gutiérrez-Vera \|e verfasserin \|4 aut
700	0		\|a Cristián Gutiérrez-Vera \|e verfasserin \|4 aut
700	0		\|a Richard García-Betancourt \|e verfasserin \|4 aut
700	0		\|a Richard García-Betancourt \|e verfasserin \|4 aut
700	0		\|a Pablo A. Palacios \|e verfasserin \|4 aut
700	0		\|a Pablo A. Palacios \|e verfasserin \|4 aut
700	0		\|a Marioly Müller \|e verfasserin \|4 aut
700	0		\|a David A. Montero \|e verfasserin \|4 aut
700	0		\|a David A. Montero \|e verfasserin \|4 aut
700	0		\|a Carlos Verdugo \|e verfasserin \|4 aut
700	0		\|a Carlos Verdugo \|e verfasserin \|4 aut
700	0		\|a Francisca Ortiz \|e verfasserin \|4 aut
700	0		\|a Francisca Ortiz \|e verfasserin \|4 aut
700	0		\|a Felipe Simon \|e verfasserin \|4 aut
700	0		\|a Felipe Simon \|e verfasserin \|4 aut
700	0		\|a Alexis M. Kalergis \|e verfasserin \|4 aut
700	0		\|a Alexis M. Kalergis \|e verfasserin \|4 aut
700	0		\|a Pablo A. González \|e verfasserin \|4 aut
700	0		\|a Pablo A. González \|e verfasserin \|4 aut
700	0		\|a Noemi A. Saavedra-Avila \|e verfasserin \|4 aut
700	0		\|a Steven A. Porcelli \|e verfasserin \|4 aut
700	0		\|a Leandro J. Carreño \|e verfasserin \|4 aut
700	0		\|a Leandro J. Carreño \|e verfasserin \|4 aut
773	0	8	\|i In \|t Frontiers in Immunology \|d Frontiers Media S.A., 2011 \|g 15(2024) \|w (DE-627)657998354 \|w (DE-600)2606827-8 \|x 16643224 \|7 nnns
773	1	8	\|g volume:15 \|g year:2024
856	4	0	\|u https://doi.org/10.3389/fimmu.2024.1364774 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/55b69705c197419b983dae990d8a8d06 \|z kostenfrei
856	4	0	\|u https://www.frontiersin.org/articles/10.3389/fimmu.2024.1364774/full \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1664-3224 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 15 \|j 2024

Indexfelder

author_variant	c g v cgv c g v cgv c g v cgv r g b rgb r g b rgb p a p pap p a p pap m m mm d a m dam d a m dam c v cv c v cv f o fo f o fo f s fs f s fs a m k amk a m k amk p a g pag p a g pag n a s a nasa s a p sap l j c ljc l j c ljc
matchkey_str	article:16643224:2024----::auakletelialriatmipiainfrhdvlpetfoeim
hierarchy_sort_str	2024
callnumber-subject-code	RC
publishDate	2024
allfields	10.3389/fimmu.2024.1364774 doi (DE-627)DOAJ09248204X (DE-599)DOAJ55b69705c197419b983dae990d8a8d06 DE-627 ger DE-627 rakwb eng RC581-607 Cristián Gutiérrez-Vera verfasserin aut Natural killer T cells in allergic asthma: implications for the development of novel immunotherapeutical strategies 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Allergic asthma has emerged as a prevalent allergic disease worldwide, affecting most prominently both young individuals and lower-income populations in developing and developed countries. To devise effective and curative immunotherapy, it is crucial to comprehend the intricate nature of this condition, characterized by an immune response imbalance that favors a proinflammatory profile orchestrated by diverse subsets of immune cells. Although the involvement of Natural Killer T (NKT) cells in asthma pathology is frequently implied, their specific contributions to disease onset and progression remain incompletely understood. Given their remarkable ability to modulate the immune response through the rapid secretion of various cytokines, NKT cells represent a promising target for the development of effective immunotherapy against allergic asthma. This review provides a comprehensive summary of the current understanding of NKT cells in the context of allergic asthma, along with novel therapeutic approaches that leverage the functional response of these cells. natural killer T cells allergic diseases asthma immunomodulation immunotherapy Immunologic diseases. Allergy Cristián Gutiérrez-Vera verfasserin aut Cristián Gutiérrez-Vera verfasserin aut Richard García-Betancourt verfasserin aut Richard García-Betancourt verfasserin aut Pablo A. Palacios verfasserin aut Pablo A. Palacios verfasserin aut Marioly Müller verfasserin aut David A. Montero verfasserin aut David A. Montero verfasserin aut Carlos Verdugo verfasserin aut Carlos Verdugo verfasserin aut Francisca Ortiz verfasserin aut Francisca Ortiz verfasserin aut Felipe Simon verfasserin aut Felipe Simon verfasserin aut Alexis M. Kalergis verfasserin aut Alexis M. Kalergis verfasserin aut Pablo A. González verfasserin aut Pablo A. González verfasserin aut Noemi A. Saavedra-Avila verfasserin aut Steven A. Porcelli verfasserin aut Leandro J. Carreño verfasserin aut Leandro J. Carreño verfasserin aut In Frontiers in Immunology Frontiers Media S.A., 2011 15(2024) (DE-627)657998354 (DE-600)2606827-8 16643224 nnns volume:15 year:2024 https://doi.org/10.3389/fimmu.2024.1364774 kostenfrei https://doaj.org/article/55b69705c197419b983dae990d8a8d06 kostenfrei https://www.frontiersin.org/articles/10.3389/fimmu.2024.1364774/full kostenfrei https://doaj.org/toc/1664-3224 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 15 2024
spelling	10.3389/fimmu.2024.1364774 doi (DE-627)DOAJ09248204X (DE-599)DOAJ55b69705c197419b983dae990d8a8d06 DE-627 ger DE-627 rakwb eng RC581-607 Cristián Gutiérrez-Vera verfasserin aut Natural killer T cells in allergic asthma: implications for the development of novel immunotherapeutical strategies 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Allergic asthma has emerged as a prevalent allergic disease worldwide, affecting most prominently both young individuals and lower-income populations in developing and developed countries. To devise effective and curative immunotherapy, it is crucial to comprehend the intricate nature of this condition, characterized by an immune response imbalance that favors a proinflammatory profile orchestrated by diverse subsets of immune cells. Although the involvement of Natural Killer T (NKT) cells in asthma pathology is frequently implied, their specific contributions to disease onset and progression remain incompletely understood. Given their remarkable ability to modulate the immune response through the rapid secretion of various cytokines, NKT cells represent a promising target for the development of effective immunotherapy against allergic asthma. This review provides a comprehensive summary of the current understanding of NKT cells in the context of allergic asthma, along with novel therapeutic approaches that leverage the functional response of these cells. natural killer T cells allergic diseases asthma immunomodulation immunotherapy Immunologic diseases. Allergy Cristián Gutiérrez-Vera verfasserin aut Cristián Gutiérrez-Vera verfasserin aut Richard García-Betancourt verfasserin aut Richard García-Betancourt verfasserin aut Pablo A. Palacios verfasserin aut Pablo A. Palacios verfasserin aut Marioly Müller verfasserin aut David A. Montero verfasserin aut David A. Montero verfasserin aut Carlos Verdugo verfasserin aut Carlos Verdugo verfasserin aut Francisca Ortiz verfasserin aut Francisca Ortiz verfasserin aut Felipe Simon verfasserin aut Felipe Simon verfasserin aut Alexis M. Kalergis verfasserin aut Alexis M. Kalergis verfasserin aut Pablo A. González verfasserin aut Pablo A. González verfasserin aut Noemi A. Saavedra-Avila verfasserin aut Steven A. Porcelli verfasserin aut Leandro J. Carreño verfasserin aut Leandro J. Carreño verfasserin aut In Frontiers in Immunology Frontiers Media S.A., 2011 15(2024) (DE-627)657998354 (DE-600)2606827-8 16643224 nnns volume:15 year:2024 https://doi.org/10.3389/fimmu.2024.1364774 kostenfrei https://doaj.org/article/55b69705c197419b983dae990d8a8d06 kostenfrei https://www.frontiersin.org/articles/10.3389/fimmu.2024.1364774/full kostenfrei https://doaj.org/toc/1664-3224 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 15 2024
allfields_unstemmed	10.3389/fimmu.2024.1364774 doi (DE-627)DOAJ09248204X (DE-599)DOAJ55b69705c197419b983dae990d8a8d06 DE-627 ger DE-627 rakwb eng RC581-607 Cristián Gutiérrez-Vera verfasserin aut Natural killer T cells in allergic asthma: implications for the development of novel immunotherapeutical strategies 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Allergic asthma has emerged as a prevalent allergic disease worldwide, affecting most prominently both young individuals and lower-income populations in developing and developed countries. To devise effective and curative immunotherapy, it is crucial to comprehend the intricate nature of this condition, characterized by an immune response imbalance that favors a proinflammatory profile orchestrated by diverse subsets of immune cells. Although the involvement of Natural Killer T (NKT) cells in asthma pathology is frequently implied, their specific contributions to disease onset and progression remain incompletely understood. Given their remarkable ability to modulate the immune response through the rapid secretion of various cytokines, NKT cells represent a promising target for the development of effective immunotherapy against allergic asthma. This review provides a comprehensive summary of the current understanding of NKT cells in the context of allergic asthma, along with novel therapeutic approaches that leverage the functional response of these cells. natural killer T cells allergic diseases asthma immunomodulation immunotherapy Immunologic diseases. Allergy Cristián Gutiérrez-Vera verfasserin aut Cristián Gutiérrez-Vera verfasserin aut Richard García-Betancourt verfasserin aut Richard García-Betancourt verfasserin aut Pablo A. Palacios verfasserin aut Pablo A. Palacios verfasserin aut Marioly Müller verfasserin aut David A. Montero verfasserin aut David A. Montero verfasserin aut Carlos Verdugo verfasserin aut Carlos Verdugo verfasserin aut Francisca Ortiz verfasserin aut Francisca Ortiz verfasserin aut Felipe Simon verfasserin aut Felipe Simon verfasserin aut Alexis M. Kalergis verfasserin aut Alexis M. Kalergis verfasserin aut Pablo A. González verfasserin aut Pablo A. González verfasserin aut Noemi A. Saavedra-Avila verfasserin aut Steven A. Porcelli verfasserin aut Leandro J. Carreño verfasserin aut Leandro J. Carreño verfasserin aut In Frontiers in Immunology Frontiers Media S.A., 2011 15(2024) (DE-627)657998354 (DE-600)2606827-8 16643224 nnns volume:15 year:2024 https://doi.org/10.3389/fimmu.2024.1364774 kostenfrei https://doaj.org/article/55b69705c197419b983dae990d8a8d06 kostenfrei https://www.frontiersin.org/articles/10.3389/fimmu.2024.1364774/full kostenfrei https://doaj.org/toc/1664-3224 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 15 2024
allfieldsGer	10.3389/fimmu.2024.1364774 doi (DE-627)DOAJ09248204X (DE-599)DOAJ55b69705c197419b983dae990d8a8d06 DE-627 ger DE-627 rakwb eng RC581-607 Cristián Gutiérrez-Vera verfasserin aut Natural killer T cells in allergic asthma: implications for the development of novel immunotherapeutical strategies 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Allergic asthma has emerged as a prevalent allergic disease worldwide, affecting most prominently both young individuals and lower-income populations in developing and developed countries. To devise effective and curative immunotherapy, it is crucial to comprehend the intricate nature of this condition, characterized by an immune response imbalance that favors a proinflammatory profile orchestrated by diverse subsets of immune cells. Although the involvement of Natural Killer T (NKT) cells in asthma pathology is frequently implied, their specific contributions to disease onset and progression remain incompletely understood. Given their remarkable ability to modulate the immune response through the rapid secretion of various cytokines, NKT cells represent a promising target for the development of effective immunotherapy against allergic asthma. This review provides a comprehensive summary of the current understanding of NKT cells in the context of allergic asthma, along with novel therapeutic approaches that leverage the functional response of these cells. natural killer T cells allergic diseases asthma immunomodulation immunotherapy Immunologic diseases. Allergy Cristián Gutiérrez-Vera verfasserin aut Cristián Gutiérrez-Vera verfasserin aut Richard García-Betancourt verfasserin aut Richard García-Betancourt verfasserin aut Pablo A. Palacios verfasserin aut Pablo A. Palacios verfasserin aut Marioly Müller verfasserin aut David A. Montero verfasserin aut David A. Montero verfasserin aut Carlos Verdugo verfasserin aut Carlos Verdugo verfasserin aut Francisca Ortiz verfasserin aut Francisca Ortiz verfasserin aut Felipe Simon verfasserin aut Felipe Simon verfasserin aut Alexis M. Kalergis verfasserin aut Alexis M. Kalergis verfasserin aut Pablo A. González verfasserin aut Pablo A. González verfasserin aut Noemi A. Saavedra-Avila verfasserin aut Steven A. Porcelli verfasserin aut Leandro J. Carreño verfasserin aut Leandro J. Carreño verfasserin aut In Frontiers in Immunology Frontiers Media S.A., 2011 15(2024) (DE-627)657998354 (DE-600)2606827-8 16643224 nnns volume:15 year:2024 https://doi.org/10.3389/fimmu.2024.1364774 kostenfrei https://doaj.org/article/55b69705c197419b983dae990d8a8d06 kostenfrei https://www.frontiersin.org/articles/10.3389/fimmu.2024.1364774/full kostenfrei https://doaj.org/toc/1664-3224 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 15 2024
allfieldsSound	10.3389/fimmu.2024.1364774 doi (DE-627)DOAJ09248204X (DE-599)DOAJ55b69705c197419b983dae990d8a8d06 DE-627 ger DE-627 rakwb eng RC581-607 Cristián Gutiérrez-Vera verfasserin aut Natural killer T cells in allergic asthma: implications for the development of novel immunotherapeutical strategies 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Allergic asthma has emerged as a prevalent allergic disease worldwide, affecting most prominently both young individuals and lower-income populations in developing and developed countries. To devise effective and curative immunotherapy, it is crucial to comprehend the intricate nature of this condition, characterized by an immune response imbalance that favors a proinflammatory profile orchestrated by diverse subsets of immune cells. Although the involvement of Natural Killer T (NKT) cells in asthma pathology is frequently implied, their specific contributions to disease onset and progression remain incompletely understood. Given their remarkable ability to modulate the immune response through the rapid secretion of various cytokines, NKT cells represent a promising target for the development of effective immunotherapy against allergic asthma. This review provides a comprehensive summary of the current understanding of NKT cells in the context of allergic asthma, along with novel therapeutic approaches that leverage the functional response of these cells. natural killer T cells allergic diseases asthma immunomodulation immunotherapy Immunologic diseases. Allergy Cristián Gutiérrez-Vera verfasserin aut Cristián Gutiérrez-Vera verfasserin aut Richard García-Betancourt verfasserin aut Richard García-Betancourt verfasserin aut Pablo A. Palacios verfasserin aut Pablo A. Palacios verfasserin aut Marioly Müller verfasserin aut David A. Montero verfasserin aut David A. Montero verfasserin aut Carlos Verdugo verfasserin aut Carlos Verdugo verfasserin aut Francisca Ortiz verfasserin aut Francisca Ortiz verfasserin aut Felipe Simon verfasserin aut Felipe Simon verfasserin aut Alexis M. Kalergis verfasserin aut Alexis M. Kalergis verfasserin aut Pablo A. González verfasserin aut Pablo A. González verfasserin aut Noemi A. Saavedra-Avila verfasserin aut Steven A. Porcelli verfasserin aut Leandro J. Carreño verfasserin aut Leandro J. Carreño verfasserin aut In Frontiers in Immunology Frontiers Media S.A., 2011 15(2024) (DE-627)657998354 (DE-600)2606827-8 16643224 nnns volume:15 year:2024 https://doi.org/10.3389/fimmu.2024.1364774 kostenfrei https://doaj.org/article/55b69705c197419b983dae990d8a8d06 kostenfrei https://www.frontiersin.org/articles/10.3389/fimmu.2024.1364774/full kostenfrei https://doaj.org/toc/1664-3224 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 15 2024
language	English
source	In Frontiers in Immunology 15(2024) volume:15 year:2024
sourceStr	In Frontiers in Immunology 15(2024) volume:15 year:2024
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	natural killer T cells allergic diseases asthma immunomodulation immunotherapy Immunologic diseases. Allergy
isfreeaccess_bool	true
container_title	Frontiers in Immunology
authorswithroles_txt_mv	Cristián Gutiérrez-Vera @@aut@@ Richard García-Betancourt @@aut@@ Pablo A. Palacios @@aut@@ Marioly Müller @@aut@@ David A. Montero @@aut@@ Carlos Verdugo @@aut@@ Francisca Ortiz @@aut@@ Felipe Simon @@aut@@ Alexis M. Kalergis @@aut@@ Pablo A. González @@aut@@ Noemi A. Saavedra-Avila @@aut@@ Steven A. Porcelli @@aut@@ Leandro J. Carreño @@aut@@
publishDateDaySort_date	2024-01-01T00:00:00Z
hierarchy_top_id	657998354
id	DOAJ09248204X
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ09248204X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414123926.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240412s2024 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3389/fimmu.2024.1364774</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ09248204X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ55b69705c197419b983dae990d8a8d06</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC581-607</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Cristián Gutiérrez-Vera</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Natural killer T cells in allergic asthma: implications for the development of novel immunotherapeutical strategies</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2024</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Allergic asthma has emerged as a prevalent allergic disease worldwide, affecting most prominently both young individuals and lower-income populations in developing and developed countries. To devise effective and curative immunotherapy, it is crucial to comprehend the intricate nature of this condition, characterized by an immune response imbalance that favors a proinflammatory profile orchestrated by diverse subsets of immune cells. Although the involvement of Natural Killer T (NKT) cells in asthma pathology is frequently implied, their specific contributions to disease onset and progression remain incompletely understood. Given their remarkable ability to modulate the immune response through the rapid secretion of various cytokines, NKT cells represent a promising target for the development of effective immunotherapy against allergic asthma. This review provides a comprehensive summary of the current understanding of NKT cells in the context of allergic asthma, along with novel therapeutic approaches that leverage the functional response of these cells.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">natural killer T cells</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">allergic diseases</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">asthma</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">immunomodulation</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">immunotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Immunologic diseases. Allergy</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Cristián Gutiérrez-Vera</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Cristián Gutiérrez-Vera</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Richard García-Betancourt</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Richard García-Betancourt</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pablo A. Palacios</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pablo A. Palacios</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Marioly Müller</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">David A. Montero</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">David A. Montero</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Carlos Verdugo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Carlos Verdugo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Francisca Ortiz</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Francisca Ortiz</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Felipe Simon</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Felipe Simon</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alexis M. Kalergis</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alexis M. Kalergis</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pablo A. González</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pablo A. González</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Noemi A. Saavedra-Avila</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Steven A. Porcelli</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Leandro J. Carreño</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Leandro J. Carreño</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Frontiers in Immunology</subfield><subfield code="d">Frontiers Media S.A., 2011</subfield><subfield code="g">15(2024)</subfield><subfield code="w">(DE-627)657998354</subfield><subfield code="w">(DE-600)2606827-8</subfield><subfield code="x">16643224</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:15</subfield><subfield code="g">year:2024</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3389/fimmu.2024.1364774</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/55b69705c197419b983dae990d8a8d06</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.frontiersin.org/articles/10.3389/fimmu.2024.1364774/full</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1664-3224</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">15</subfield><subfield code="j">2024</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Cristián Gutiérrez-Vera
spellingShingle	Cristián Gutiérrez-Vera misc RC581-607 misc natural killer T cells misc allergic diseases misc asthma misc immunomodulation misc immunotherapy misc Immunologic diseases. Allergy Natural killer T cells in allergic asthma: implications for the development of novel immunotherapeutical strategies
authorStr	Cristián Gutiérrez-Vera
ppnlink_with_tag_str_mv	@@773@@(DE-627)657998354
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC581-607
illustrated	Not Illustrated
issn	16643224
topic_title	RC581-607 Natural killer T cells in allergic asthma: implications for the development of novel immunotherapeutical strategies natural killer T cells allergic diseases asthma immunomodulation immunotherapy
topic	misc RC581-607 misc natural killer T cells misc allergic diseases misc asthma misc immunomodulation misc immunotherapy misc Immunologic diseases. Allergy
topic_unstemmed	misc RC581-607 misc natural killer T cells misc allergic diseases misc asthma misc immunomodulation misc immunotherapy misc Immunologic diseases. Allergy
topic_browse	misc RC581-607 misc natural killer T cells misc allergic diseases misc asthma misc immunomodulation misc immunotherapy misc Immunologic diseases. Allergy
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Frontiers in Immunology
hierarchy_parent_id	657998354
hierarchy_top_title	Frontiers in Immunology
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)657998354 (DE-600)2606827-8
title	Natural killer T cells in allergic asthma: implications for the development of novel immunotherapeutical strategies
ctrlnum	(DE-627)DOAJ09248204X (DE-599)DOAJ55b69705c197419b983dae990d8a8d06
title_full	Natural killer T cells in allergic asthma: implications for the development of novel immunotherapeutical strategies
author_sort	Cristián Gutiérrez-Vera
journal	Frontiers in Immunology
journalStr	Frontiers in Immunology
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2024
contenttype_str_mv	txt
author_browse	Cristián Gutiérrez-Vera Richard García-Betancourt Pablo A. Palacios Marioly Müller David A. Montero Carlos Verdugo Francisca Ortiz Felipe Simon Alexis M. Kalergis Pablo A. González Noemi A. Saavedra-Avila Steven A. Porcelli Leandro J. Carreño
container_volume	15
class	RC581-607
format_se	Elektronische Aufsätze
author-letter	Cristián Gutiérrez-Vera
doi_str_mv	10.3389/fimmu.2024.1364774
author2-role	verfasserin
title_sort	natural killer t cells in allergic asthma: implications for the development of novel immunotherapeutical strategies
callnumber	RC581-607
title_auth	Natural killer T cells in allergic asthma: implications for the development of novel immunotherapeutical strategies
abstract	Allergic asthma has emerged as a prevalent allergic disease worldwide, affecting most prominently both young individuals and lower-income populations in developing and developed countries. To devise effective and curative immunotherapy, it is crucial to comprehend the intricate nature of this condition, characterized by an immune response imbalance that favors a proinflammatory profile orchestrated by diverse subsets of immune cells. Although the involvement of Natural Killer T (NKT) cells in asthma pathology is frequently implied, their specific contributions to disease onset and progression remain incompletely understood. Given their remarkable ability to modulate the immune response through the rapid secretion of various cytokines, NKT cells represent a promising target for the development of effective immunotherapy against allergic asthma. This review provides a comprehensive summary of the current understanding of NKT cells in the context of allergic asthma, along with novel therapeutic approaches that leverage the functional response of these cells.
abstractGer	Allergic asthma has emerged as a prevalent allergic disease worldwide, affecting most prominently both young individuals and lower-income populations in developing and developed countries. To devise effective and curative immunotherapy, it is crucial to comprehend the intricate nature of this condition, characterized by an immune response imbalance that favors a proinflammatory profile orchestrated by diverse subsets of immune cells. Although the involvement of Natural Killer T (NKT) cells in asthma pathology is frequently implied, their specific contributions to disease onset and progression remain incompletely understood. Given their remarkable ability to modulate the immune response through the rapid secretion of various cytokines, NKT cells represent a promising target for the development of effective immunotherapy against allergic asthma. This review provides a comprehensive summary of the current understanding of NKT cells in the context of allergic asthma, along with novel therapeutic approaches that leverage the functional response of these cells.
abstract_unstemmed	Allergic asthma has emerged as a prevalent allergic disease worldwide, affecting most prominently both young individuals and lower-income populations in developing and developed countries. To devise effective and curative immunotherapy, it is crucial to comprehend the intricate nature of this condition, characterized by an immune response imbalance that favors a proinflammatory profile orchestrated by diverse subsets of immune cells. Although the involvement of Natural Killer T (NKT) cells in asthma pathology is frequently implied, their specific contributions to disease onset and progression remain incompletely understood. Given their remarkable ability to modulate the immune response through the rapid secretion of various cytokines, NKT cells represent a promising target for the development of effective immunotherapy against allergic asthma. This review provides a comprehensive summary of the current understanding of NKT cells in the context of allergic asthma, along with novel therapeutic approaches that leverage the functional response of these cells.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
title_short	Natural killer T cells in allergic asthma: implications for the development of novel immunotherapeutical strategies
url	https://doi.org/10.3389/fimmu.2024.1364774 https://doaj.org/article/55b69705c197419b983dae990d8a8d06 https://www.frontiersin.org/articles/10.3389/fimmu.2024.1364774/full https://doaj.org/toc/1664-3224
remote_bool	true
author2	Cristián Gutiérrez-Vera Richard García-Betancourt Pablo A. Palacios Marioly Müller David A. Montero Carlos Verdugo Francisca Ortiz Felipe Simon Alexis M. Kalergis Pablo A. González Noemi A. Saavedra-Avila Steven A. Porcelli Leandro J. Carreño
author2Str	Cristián Gutiérrez-Vera Richard García-Betancourt Pablo A. Palacios Marioly Müller David A. Montero Carlos Verdugo Francisca Ortiz Felipe Simon Alexis M. Kalergis Pablo A. González Noemi A. Saavedra-Avila Steven A. Porcelli Leandro J. Carreño
ppnlink	657998354
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.3389/fimmu.2024.1364774
callnumber-a	RC581-607
up_date	2024-07-04T01:29:52.045Z
_version_	1803610061072760832
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ09248204X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414123926.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240412s2024 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3389/fimmu.2024.1364774</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ09248204X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ55b69705c197419b983dae990d8a8d06</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC581-607</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Cristián Gutiérrez-Vera</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Natural killer T cells in allergic asthma: implications for the development of novel immunotherapeutical strategies</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2024</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Allergic asthma has emerged as a prevalent allergic disease worldwide, affecting most prominently both young individuals and lower-income populations in developing and developed countries. To devise effective and curative immunotherapy, it is crucial to comprehend the intricate nature of this condition, characterized by an immune response imbalance that favors a proinflammatory profile orchestrated by diverse subsets of immune cells. Although the involvement of Natural Killer T (NKT) cells in asthma pathology is frequently implied, their specific contributions to disease onset and progression remain incompletely understood. Given their remarkable ability to modulate the immune response through the rapid secretion of various cytokines, NKT cells represent a promising target for the development of effective immunotherapy against allergic asthma. This review provides a comprehensive summary of the current understanding of NKT cells in the context of allergic asthma, along with novel therapeutic approaches that leverage the functional response of these cells.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">natural killer T cells</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">allergic diseases</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">asthma</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">immunomodulation</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">immunotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Immunologic diseases. Allergy</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Cristián Gutiérrez-Vera</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Cristián Gutiérrez-Vera</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Richard García-Betancourt</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Richard García-Betancourt</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pablo A. Palacios</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pablo A. Palacios</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Marioly Müller</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">David A. Montero</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">David A. Montero</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Carlos Verdugo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Carlos Verdugo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Francisca Ortiz</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Francisca Ortiz</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Felipe Simon</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Felipe Simon</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alexis M. Kalergis</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alexis M. Kalergis</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pablo A. González</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pablo A. González</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Noemi A. Saavedra-Avila</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Steven A. Porcelli</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Leandro J. Carreño</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Leandro J. Carreño</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Frontiers in Immunology</subfield><subfield code="d">Frontiers Media S.A., 2011</subfield><subfield code="g">15(2024)</subfield><subfield code="w">(DE-627)657998354</subfield><subfield code="w">(DE-600)2606827-8</subfield><subfield code="x">16643224</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:15</subfield><subfield code="g">year:2024</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3389/fimmu.2024.1364774</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/55b69705c197419b983dae990d8a8d06</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.frontiersin.org/articles/10.3389/fimmu.2024.1364774/full</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1664-3224</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">15</subfield><subfield code="j">2024</subfield></datafield></record></collection>
score	7.4021244

Nicht das Richtige dabei?

Schreiben Sie uns!

Natural killer T cells in allergic asthma: implications for the development of novel immunotherapeutical strategies

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?